Business
New Data Demonstrate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier in Tailoring Treatment for Prostate Cancer Patients Experiencing Progression After Surgery
Findings shared today in an oral presentation at ASTRO Annual Meeting 2021 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT)
About this update from Veracyte, Inc.
[{"type":"text","content":"\nFindings shared today in an oral presentation at ASTRO Annual Meeting 2021\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nVeracyte, Inc. (Nasdaq: VCYT) announced new data demonstrating the clinical utility of the company’s Decipher Prostate genomic classifier for guiding the timing and intensity of treatment in men experiencing prostate cancer progression following radical prostatectomy. The data, from a randomized, phase 3 trial conducted at 24 centers in Belgium, Germany, and Switzerland (SAKK 09/10), were presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2021 (abstract #94).\n\nFollowing radical prostatectomy, physicians typically monitor prostate cancer patients’ prostate-specific antigen (PSA) to identify biochemical recurrence. For those men who experience a subsequent rise in PSA, determining the optimal timing to initiate treatment and whether to add androgen deprivation therapy (ADT) to radiotherapy is challenging. Conventional clinical measures such as PSA and pathological findings following surgery are often insufficient to predict which patients will experience favorable oncologic outcomes with radiotherapy alone, and which will have disease that continues to progress.\n\nTo determine whether the Decipher Prostate genomic classifier could help identify those patients who would benefit from earlier intervention with radiotherapy or the addition of ADT to radiotherapy in this setting, researchers in the Swiss Group for Clinical Cancer Research (SAKK) and collaborating cancer centers assessed the outcomes and Decipher Prostate genomic risk for 226 prostate cancer patients from the SAKK 09/10 phase 3 randomized clinical trial. This study involved men experiencing a rise in PSA following radical prostatectomy, all of whom received radiotherapy without the addition of ADT. Patients in the Decipher Prostate analysis were followed for a median of 6.3 years.\n\n“We’re pleased to have participated in this study, which explored a critical decision point in the management of men with prostate cancer,” said Elai Davicioni, Ph.D., Veracyte’s senior vice president of Scientific and Clinical Operations, Urologic Cancers. “The side effects of ADT when given concurrently with radiotherapy are often difficult for patients to manage. Being able to identify those patients who are likely to have ...